Tracers / [188Re]Re-ReO4

[188Re]Re-ReO4

Also written as [Re-188]ReO4

Radionuclide: Re-188 t½ 1020 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 2

Radiolabelling starting material

What it is

Compound class: perrhenate ([188Re]ReO4−), starting material for radiolabeling of monoclonal antibodies
Target / mechanism: —
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	—	[188Re]ReO4−	28951872 2017 Biomed Res Int This simple method, known as "direct radiolabeling," has been proved in the past to be a promising approach.
—	—	—	—	—	—	10698233 2000 J Nucl Cardiol

Need this precursor?We can point you to suppliers for [188Re]Re-ReO4, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 28951872: 'the reaction of the tetraoxo anion [188Re]ReO4− with SnCl2'.